---
schema_version: "secwatch.filing_event.v1"
accession: "0001576280-25-000043"
form_type: "8-K"
ticker: "GH"
cik: "0001576280"
company_name: "Guardant Health, Inc."
filed_at: "2025-02-20T23:59:59+00:00"
generated_at: "2026-05-26T08:49:37.081286+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Guardant Health Q4 revenue up 30% to $201.8M; 2025 revenue guidance $850-860M, convertible debt exchanged

## Summary
- Full-year 2024 revenue $739M (+31% YoY); net loss $436.4M ($3.56 loss per share); non-GAAP net loss $247.2M ($2.01 loss per share).
- Q4 2024 revenue $201.8M (+30% YoY); net loss $111M ($0.90 loss per share); non-GAAP net loss $77.3M ($0.62 loss per share).
- Completed convertible debt exchange: issued $600M 1.25% 2031 notes, retiring $659.3M of 0% 2027 notes; also repurchased $45M of common stock.
- 2025 guidance: revenue $850-860M (15-16% growth); oncology clinical volume growth expected to accelerate to ~25%; screening revenue $25-30M on 45-50K Shield tests.
- Free cash flow burn improved to $275M in 2024; expects $225-235M in 2025; Guardant Reveal received Medicare coverage for CRC surveillance.

## SEC filing metadata
- accession: 0001576280-25-000043
- form_type: 8-K
- ticker: GH
- cik: 0001576280
- company_name: Guardant Health, Inc.
- filed_at: 2025-02-20T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1576280/000157628025000043/0001576280-25-000043-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1576280/000157628025000043/gh-20250220.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001576280-25-000043
- JSON: https://secwatch.observer/filing/0001576280-25-000043.json
- Plain text: https://secwatch.observer/filing/0001576280-25-000043.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.